Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price objective upped by equities researchers at Needham & Company LLC from $36.00 to $40.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 47.60% from the stock’s current price.

A number of other research firms have also issued reports on ARQT. Wall Street Zen upgraded shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.67.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $27.10 on Thursday. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54. The company has a market cap of $3.39 billion, a PE ratio of -903.03 and a beta of 1.49. The company’s fifty day simple moving average is $25.87 and its 200-day simple moving average is $24.68. Arcutis Biotherapeutics has a 52 week low of $13.69 and a 52 week high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The firm had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. As a group, equities research analysts anticipate that Arcutis Biotherapeutics will post 0.16 EPS for the current year.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 4,375 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the sale, the insider directly owned 717,203 shares in the company, valued at approximately $18,733,342.36. This trade represents a 0.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sue-Jean Lin sold 4,946 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.38, for a total transaction of $120,583.48. Following the completion of the sale, the director owned 27,567 shares of the company’s stock, valued at approximately $672,083.46. The trade was a 15.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 16,894 shares of company stock worth $422,044 over the last ninety days. Insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ARQT. SBI Securities Co. Ltd. boosted its holdings in Arcutis Biotherapeutics by 325.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after purchasing an additional 833 shares in the last quarter. Global Retirement Partners LLC bought a new position in Arcutis Biotherapeutics during the fourth quarter valued at about $35,000. EverSource Wealth Advisors LLC lifted its position in shares of Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after buying an additional 698 shares during the last quarter. NewEdge Advisors LLC lifted its position in shares of Arcutis Biotherapeutics by 209.0% in the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after buying an additional 1,045 shares during the last quarter. Finally, Truvestments Capital LLC boosted its stake in shares of Arcutis Biotherapeutics by 114.2% during the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock worth $87,000 after acquiring an additional 1,606 shares in the last quarter.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Q2 results exceeded expectations: Arcutis reported earnings of $0.11 per share, above estimates of $0.06–$0.09 and substantially better than the $0.13-per-share loss recorded a year earlier. Revenue reached $129.9 million, beating the $118.9 million consensus estimate and increasing 59% year over year. Arcutis second-quarter 2026 results
• Positive Sentiment: Higher sales outlook: Management raised 2026 net product sales guidance to $525 million–$540 million, reflecting continued demand for ZORYVE. The company also reported positive operating cash flow for the quarter, supporting the improving commercial profile. Arcutis business update
• Positive Sentiment: Regulatory and pipeline catalysts expanded: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. An application covering infants aged three to 24 months with atopic dermatitis was accepted for review, with a February 23, 2027 target action date. Enrollment also concluded in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. ZORYVE regulatory and pipeline update
• Neutral Sentiment: Insider selling was limited: Three insiders sold a combined 6,560 shares worth approximately $171,000. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax obligations from vested equity awards, reducing their value as a bearish signal. ARQT insider transactions

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.